Sign up for ICER's Weekly View Newsletter

 

Weekly View


July 24, 2026

From the desk of Priya Ranade

Good morning, everyone.

Next week, ICER will be publishing two reports:



  • A Final Evidence Report on vaccines for Covid-19, which includes a summary of the June 25th ICER public meeting on the topic.

 

Both reports are following ICER's eight-month report development process. We try to make our process as transparent as possible: we post more than seven iterative documents along the way, we provide two public comment periods, and we host a public meeting to discuss the comparative clinical and cost effectiveness. 


We also include numerous opportunities for stakeholders to engage. And, we are always looking for new ways to incorporate constructive feedback.

Let's see what happened this week...

 

ICER in the News

 

Sorry, we just can’t cover those effective drugs

The Boston Globe

In case you missed it, The Boston Globe’s Carey Goldberg published an op-ed last week about access to GLP-1 obesity medications. ICER reviewed GLP-1s in 2022 and 2025 and found (both times) that they were cost-effective at current prices. 


Still, as the Globe article highlights, patients continue to struggle to access these transformative medications. ICER’s Chief Medical Officer, David Rind, MD, quoted in the story said: “’More and more, people have been coming in saying, ‘Insurance has informed me I’m no longer covered,’ says Rind, who teaches primary care to medical residents at Beth Israel Deaconess Medical Center. Appeals go nowhere. Lost weight returns. It’s self-pay or nothing — usually nothing. Many people can afford to pay hundreds of dollars a month for a GLP-1 drug, he says, ‘but not most of our patients’… To him, these are not just good drugs; they are once-in-a-career drugs, able to slash heart-disease risk by 20 percent among myriad other benefits.”

 

ICER’s President and CEO Sarah K. Emond, MPP, also quoted in the article, spoke to this being a symptom of the larger problem of not paying for value: “The health care system overpays for so many other drugs that ‘then, when you have something high-value available for a large population, you feel like you don’t have any money left for it.’”

How Revenue Cycle Management (RCM) Became an Over $200 Billion Healthcare Hot Potato, With Andrew Tsang

Relentless Health Value (podcast)

This week's Relentless Health podcast with Stacey Richter dives into revenue cycle management with health care writer and consultant, Andrew Tsang. Towards the end of the conversation, Stacey mentions a previous episode with ICER's President and CEO, Sarah Emond:


"Stacey Richter: I think in the past it's been 5% of plan members or about 50% of the costs. I just heard someone say the other day that these days, just given the cell and gene that you were talking about, given just the medical advances, that 2% of plan members are gonna be 50% of the cost in any given plan year.


And to your exact point, I definitely would go back and listen to the episode with Sarah Emond because she makes this point very crisply. These are medical miracles. We're saving people's lives, like people that had a death sentence now have the potential to be saved. In her parlance these are high value therapies. At the same time, however, who's gonna pay for this?"


To listen to Sarah's full episode on the "Six Tensions of Pharmaceutical Drug Pricing", click here.

When Does Data Expire? A Novo Nordisk Lawsuit Against Eli Lilly Is About to Find Out

Inc Magazine

Novo Nordisk sued Eli Lilly on Tuesday, seeking to stop ads saying patients lost about 50 pounds on Lilly’s Zepbound compared with 33 pounds on Novo’s Wegovy. The dispute centers on the issue of when accurate clinical data becomes too outdated to use. To better understand the data used in the ads, Inc Magazine spoke with ICER’s Chief Medical Officer, David Rind, MD:

 

“David Rind, chief medical officer at the Institute for Clinical and Economic Review, says existing studies suggest the higher Wegovy dose works better than the 2.4-milligram version but remains less effective for weight loss than 15-milligrams of tirzepatide, Zepbound’s active ingredient. Gastrointestinal side effects also increased at Wegovy’s higher dose, he says.”

Next-generation methods in health technology assessment (HTA): need, rigor, and implementability

International Journal of Technology Assessment in Health Care

ICER’s Marina Richardson, Director of Health Technology Assessment Methods and Health Economics, is a co-author on a recently published paper that captures the discussions from the 2025 Health Technology Assessment International (HTAi) Annual Meeting in Buenos Aires, Argentina. The paper summarized Plenary 2 (NextGen Methods: Hype Or Here To Stay?) one of three main plenaries at HTAi's Annual Meeting last year.

 

Marina co-moderated the plenary where each panelist was tasked to debate the need, rigor, and implementability of one of three emerging method domains in HTA: (1) Environmental Sustainability, (2) Adaptive HTA, and (3) Artificial Intelligence (AI)-enabled Real-World Evidence (RWE).

 
Pharmaceutical News

MUST READS


Trump pledges new tariffs on generic drugs not made in the US

Endpoints News

President Donald Trump on Tuesday evening said he will impose up to 200% tariffs on generic drugs sold in the US, if companies do not manufacture those medicines in America.


Trump said that for the next two years, generic companies can continue to import their products tariff-free, but in August 2028, 100% tariffs will be imposed on any generics not made in the US. And a year later, after Trump’s term expires, those tariffs will double to 200%, according to his social media post.

If It Sticks, MFN Price Deal For Semaglutide Could Save Medicare A Lot More Than Negotiated Price

Pink Sheet

Most Favored Nation pricing for Novo Nordisk’s semaglutide products could lower Medicare spending on the drugs by $1.76bn between 2026 and 2035, according to a new analysis by Sean Sullivan, University of Washington, et al. published in Value in Health.


By comparison, the 10-year savings to Medicare produced by the program’s negotiated maximum fair prices for Wegovy, Ozempic and Rybelsus would be much lower at an estimated $463m, the researchers found.

Makers of rare disease drugs seek exemption from Trump’s price-cut pilots

STAT

Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that lower brand drug prices in Medicare.


The Rare Disease Company Coalition met last week with the White House Office of Management and Budget to discuss two pilot programs that are part of President Trump’s plan to get drugmakers to lower prices in the United States to levels charged in other rich countries.

State audit of Medicaid records points to methods used by PBMs to obscure drug costs

STAT

The audit of Iowa’s state Medicaid program found that one large pharmacy benefit manager appeared to have made more than $100 million by adjusting the amount of money paid to pharmacies without passing some of the savings back to managed care plans working on behalf of the state, according to Iowa officials. The review scrutinized records from 2019 through 2021. The overall conclusion was similar to audit results conducted in a few other states.

Health insurance traps a quarter of U.S. workers in unwanted jobs

Axios

Almost a quarter of workers in the U.S. — 23 million adults — are experiencing "job lock," staying in roles they don't want to avoid losing health insurance benefits, according to a new Gallup analysis.

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 7/28: Covid-19 — Final Evidence Report
  • 7/29: Parkinson's Disease — Draft Evidence Report
  • 8/12: Hypertension — Draft Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email